Search

Your search keyword '"Meijerink, M"' showing total 321 results
Start Over Author "Meijerink, M"
321 results on '"Meijerink, M"'

1. Correction: Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design

Author

Doppenberg, D., Besselink, M. G., van Eijck, C. H. J., Intven, M. P. W., Groot Koerkamp, B., Kazemier, G., van Laarhoven, H. W. M., Meijerink, M., Molenaar, I. Q., Nuyttens, J. J. M. E., van Os, R., van Santvoort, H. C., van Tienhoven, G., Verkooijen, H. M., Versteijne, E., Wilmink, J. W., Lagerwaard, F. J., and Bruynzeel, A. M. E.

Published
2023
Full Text
View/download PDF

2. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author

Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Å., Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.

Published
2022
Full Text
View/download PDF

3. Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial

Author

Blomjous, JG, de Boer, MT, van den Boezem, P, Bouwense, S, Bruijnen, R, Buis, CI, del Chiaro, M, Coene, PP, Coolsen, M, Daams, F, Dejong, K, Draaisma, W, Eker, HH, Elsen, AH, Gerhards, MF, Hartog, H, Hoogwater, FJ, Imani, F, Jenniskens, S, de Jong, KP, Karsten, TM, Klaase, JM, de Kleine, RHJ, van Laarhoven, CJ, van der Lelij, H, Manusama, ER, Meerdink, M, Meijerink, M, Nederend, J, Nijkamp, MW, Nota, CL, Porte, RJ, Reef, J, de Reuver, P, van Rijswijk, C, Romkens, T, Rupert, C, van der Schelling, GP, Serafino, JP, Vos, LD, Vriens, MR, Beers-Vural, E, Wagtenberg, JM, Wijsman, JH, de Wilde, RF, Wolfgang, CL, Zeh, HJ, III, Smits, F Jasmijn, Henry, Anne Claire, Besselink, Marc G, Busch, Olivier R, van Eijck, Casper H, Arntz, Mark, Bollen, Thomas L, van Delden, Otto M, van den Heuvel, Daniel, van der Leij, Christiaan, van Lienden, Krijn P, Moelker, Adriaan, Bonsing, Bert A, Borel Rinkes, Inne H, Bosscha, Koop, van Dam, Ronald M, Derksen, Wouter J M, den Dulk, Marcel, Festen, Sebastiaan, Groot Koerkamp, Bas, de Haas, Robbert J, Hagendoorn, Jeroen, van der Harst, Erwin, de Hingh, Ignace H, Kazemier, Geert, van der Kolk, Marion, Liem, Mike, Lips, Daan J, Luyer, Misha D, de Meijer, Vincent E, Mieog, J Sven, Nieuwenhuijs, Vincent B, Patijn, Gijs A, te Riele, Wouter W, Roos, Daphne, Schreinemakers, Jennifer M, Stommel, Martijn W J, Wit, Fennie, Zonderhuis, Babs A, Daamen, Lois A, van Werkhoven, C Henri, Molenaar, I Quintus, and van Santvoort, Hjalmar C

Published
2022
Full Text
View/download PDF

4. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design

Author

Doppenberg, D., Besselink, M. G., van Eijck, C. H. J., Intven, M. P. W., Koerkamp, B. Groot, Kazemier, G., van Laarhoven, H. W. M., Meijerink, M., Molenaar, I. Q., Nuyttens, J. J. M. E., van Os, R., van Santvoort, H. C., van Tienhoven, G., Verkooijen, H. M., Versteijne, E., Wilmink, J. W., Lagerwaard, F. J., and Bruynzeel, A. M. E.

Published
2022
Full Text
View/download PDF

5. Beeldvorming

Author

Kist, J. W., Vogel, W. V., Hartmann, I. J. C., Lam, M. G. E. H., Meijerink, M. R., van Krieken, J.H.J.M., editor, Beets-Tan, R.G.H., editor, Gelderblom, A.J., editor, Olofsen, M.J.J., editor, and Rutten, H.J.T., editor

Published
2020
Full Text
View/download PDF

7. Multisocietal European consensus on the terminology, diagnosis, and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE

Author

Siriwardena, A, Serrablo, A, Fretland, A, Wigmore, S, Ramia-Angel, J, Malik, H, Stattner, S, Soreide, K, Zmora, O, Meijerink, M, Kartalis, N, Lesurtel, M, Verhoef, K, Balakrishnan, A, Gruenberger, T, Jonas, E, Devar, J, Jamdar, S, Jones, R, Hilal, M, Andersson, B, Boudjema, K, Mullamitha, S, Stassen, L, Dasari, B, Frampton, A, Aldrighetti, L, Pellino, G, Buchwald, P, Gurses, B, Wasserberg, N, Gruenberger, B, Spiers, H, Jarnagin, W, Vauthey, J, Kokudo, N, Tejpar, S, Valdivieso, A, Adam, R, Lang, H, Smith, M, Deoliveira, M, Adair, A, Gilg, S, Swijnenburg, R, Jaekers, J, Jegatheeswaran, S, Buis, C, Parks, R, Bockhorn, M, Conroy, T, Petras, P, Primavesi, F, Chan, A, Cipriani, F, Rubbia-Brandt, L, Foster, L, Abdelaal, A, Yaqub, S, Rahbari, N, Fondevila, C, Abradelo, M, Kok, N, Tejedor, L, Martinez-Baena, D, Azoulay, D, Maglione, M, Serradilla-Martin, M, Azevedo, J, Romano, F, Line, P, Forcen, T, Panis, Y, Stylianides, N, Bale, R, Quaia, E, Yassin, N, Duque, V, Espin-Basany, E, Mellenhorst, J, Rees, A, Adeyeye, A, Tuynman, J, Simillis, C, Duff, S, Wilson, R, De Nardi, P, Palmer, G, Zakaria, A, Perra, T, Porcu, A, Tamini, N, Kelly, M, Metwally, I, Morarasu, S, Carbone, F, Estaire-Gomez, M, Perez, E, Seligmann, J, Gollins, S, Braun, M, Hessheimer, A, Alonso, V, Radhakrishna, G, Alam, N, Camposorias, C, Barriuoso, J, Ross, P, Ba-Ssalamah, A, Muthu, S, Filobbos, R, Nadarajah, V, Hattab, A, Newton, C, Barker, S, Sibbald, J, Hancock, J, de Liguori Carino, N, Deshpande, R, Lancellotti, F, Paterna, S, Gutierrez-Diez, M, Artigas, C, Siriwardena A. K., Serrablo A., Fretland A. A., Wigmore S. J., Ramia-Angel J. M., Malik H. Z., Stattner S., Soreide K., Zmora O., Meijerink M., Kartalis N., Lesurtel M., Verhoef K., Balakrishnan A., Gruenberger T., Jonas E., Devar J., Jamdar S., Jones R., Hilal M. A., Andersson B., Boudjema K., Mullamitha S., Stassen L., Dasari B. V. M., Frampton A. E., Aldrighetti L., Pellino G., Buchwald P., Gurses B., Wasserberg N., Gruenberger B., Spiers H. V. M., Jarnagin W., Vauthey J. -N., Kokudo N., Tejpar S., Valdivieso A., Adam R., Lang H., Smith M., deOliveira M. L., Adair A., Gilg S., Swijnenburg R. -J., Jaekers J., Jegatheeswaran S., Buis C., Parks R., Bockhorn M., Conroy T., Petras P., Primavesi F., Chan A. K. C., Cipriani F., Rubbia-Brandt L., Foster L., Abdelaal A., Yaqub S., Rahbari N., Fondevila C., Abradelo M., Kok N. F. M., Tejedor L., Martinez-Baena D., Azoulay D., Maglione M., Serradilla-Martin M., Azevedo J., Romano F., Line P. -D., Forcen T. A., Panis Y., Stylianides N., Bale R., Quaia E., Yassin N., Duque V., Espin-Basany E., Mellenhorst J., Rees A., Adeyeye A., Tuynman J. B., Simillis C., Duff S., Wilson R., De Nardi P., Palmer G. J., Zakaria A. D., Perra T., Porcu A., Tamini N., Kelly M. E., Metwally I., Morarasu S., Carbone F., Estaire-Gomez M., Perez E. M., Seligmann J., Gollins S., Braun M., Hessheimer A., Alonso V., Radhakrishna G., Alam N., Camposorias C., Barriuoso J., Ross P., Ba-Ssalamah A., Muthu S., Filobbos R., Nadarajah V., Hattab A., Newton C., Barker S., Sibbald J., Hancock J., de Liguori Carino N., Deshpande R., Lancellotti F., Paterna S., Gutierrez-Diez M., Artigas C., Siriwardena, A, Serrablo, A, Fretland, A, Wigmore, S, Ramia-Angel, J, Malik, H, Stattner, S, Soreide, K, Zmora, O, Meijerink, M, Kartalis, N, Lesurtel, M, Verhoef, K, Balakrishnan, A, Gruenberger, T, Jonas, E, Devar, J, Jamdar, S, Jones, R, Hilal, M, Andersson, B, Boudjema, K, Mullamitha, S, Stassen, L, Dasari, B, Frampton, A, Aldrighetti, L, Pellino, G, Buchwald, P, Gurses, B, Wasserberg, N, Gruenberger, B, Spiers, H, Jarnagin, W, Vauthey, J, Kokudo, N, Tejpar, S, Valdivieso, A, Adam, R, Lang, H, Smith, M, Deoliveira, M, Adair, A, Gilg, S, Swijnenburg, R, Jaekers, J, Jegatheeswaran, S, Buis, C, Parks, R, Bockhorn, M, Conroy, T, Petras, P, Primavesi, F, Chan, A, Cipriani, F, Rubbia-Brandt, L, Foster, L, Abdelaal, A, Yaqub, S, Rahbari, N, Fondevila, C, Abradelo, M, Kok, N, Tejedor, L, Martinez-Baena, D, Azoulay, D, Maglione, M, Serradilla-Martin, M, Azevedo, J, Romano, F, Line, P, Forcen, T, Panis, Y, Stylianides, N, Bale, R, Quaia, E, Yassin, N, Duque, V, Espin-Basany, E, Mellenhorst, J, Rees, A, Adeyeye, A, Tuynman, J, Simillis, C, Duff, S, Wilson, R, De Nardi, P, Palmer, G, Zakaria, A, Perra, T, Porcu, A, Tamini, N, Kelly, M, Metwally, I, Morarasu, S, Carbone, F, Estaire-Gomez, M, Perez, E, Seligmann, J, Gollins, S, Braun, M, Hessheimer, A, Alonso, V, Radhakrishna, G, Alam, N, Camposorias, C, Barriuoso, J, Ross, P, Ba-Ssalamah, A, Muthu, S, Filobbos, R, Nadarajah, V, Hattab, A, Newton, C, Barker, S, Sibbald, J, Hancock, J, de Liguori Carino, N, Deshpande, R, Lancellotti, F, Paterna, S, Gutierrez-Diez, M, Artigas, C, Siriwardena A. K., Serrablo A., Fretland A. A., Wigmore S. J., Ramia-Angel J. M., Malik H. Z., Stattner S., Soreide K., Zmora O., Meijerink M., Kartalis N., Lesurtel M., Verhoef K., Balakrishnan A., Gruenberger T., Jonas E., Devar J., Jamdar S., Jones R., Hilal M. A., Andersson B., Boudjema K., Mullamitha S., Stassen L., Dasari B. V. M., Frampton A. E., Aldrighetti L., Pellino G., Buchwald P., Gurses B., Wasserberg N., Gruenberger B., Spiers H. V. M., Jarnagin W., Vauthey J. -N., Kokudo N., Tejpar S., Valdivieso A., Adam R., Lang H., Smith M., deOliveira M. L., Adair A., Gilg S., Swijnenburg R. -J., Jaekers J., Jegatheeswaran S., Buis C., Parks R., Bockhorn M., Conroy T., Petras P., Primavesi F., Chan A. K. C., Cipriani F., Rubbia-Brandt L., Foster L., Abdelaal A., Yaqub S., Rahbari N., Fondevila C., Abradelo M., Kok N. F. M., Tejedor L., Martinez-Baena D., Azoulay D., Maglione M., Serradilla-Martin M., Azevedo J., Romano F., Line P. -D., Forcen T. A., Panis Y., Stylianides N., Bale R., Quaia E., Yassin N., Duque V., Espin-Basany E., Mellenhorst J., Rees A., Adeyeye A., Tuynman J. B., Simillis C., Duff S., Wilson R., De Nardi P., Palmer G. J., Zakaria A. D., Perra T., Porcu A., Tamini N., Kelly M. E., Metwally I., Morarasu S., Carbone F., Estaire-Gomez M., Perez E. M., Seligmann J., Gollins S., Braun M., Hessheimer A., Alonso V., Radhakrishna G., Alam N., Camposorias C., Barriuoso J., Ross P., Ba-Ssalamah A., Muthu S., Filobbos R., Nadarajah V., Hattab A., Newton C., Barker S., Sibbald J., Hancock J., de Liguori Carino N., Deshpande R., Lancellotti F., Paterna S., Gutierrez-Diez M., and Artigas C.

Abstract

Background: Contemporary management of patients with synchronous colorectal cancer and liver metastases is complex. The aim of this project was to provide a practical framework for care of patients with synchronous colorectal cancer and liver metastases, with a focus on terminology, diagnosis, and management. Methods: This project was a multiorganizational, multidisciplinary consensus. The consensus group produced statements which focused on terminology, diagnosis, and management. Statements were refined during an online Delphi process, and those with 70 per cent agreement or above were reviewed at a final meeting. Iterations of the report were shared by electronic mail to arrive at a final agreed document comprising 12 key statements. Results: Synchronous liver metastases are those detected at the time of presentation of the primary tumour. The term 'early metachronous metastases' applies to those absent at presentation but detected within 12 months of diagnosis of the primary tumour, the term 'late metachronous metastases' applies to those detected after 12 months. 'Disappearing metastases' applies to lesions that are no longer detectable on MRI after systemic chemotherapy. Guidance was provided on the recommended composition of tumour boards, and clinical assessment in emergency and elective settings. The consensus focused on treatment pathways, including systemic chemotherapy, synchronous surgery, and the staged approach with either colorectal or liver-directed surgery as first step. Management of pulmonary metastases and the role of minimally invasive surgery was discussed. Conclusion: The recommendations of this contemporary consensus provide information of practical value to clinicians managing patients with synchronous colorectal cancer and liver metastases.

Published
2023

8. The multi-societal European consensus on the terminology, diagnosis and management of patients with synchronous colorectal cancer and liver metastases: an E-AHPBA consensus in partnership with ESSO, ESCP, ESGAR, and CIRSE

Author

Siriwardena, A, Serrablo, A, Fretland, A, Wigmore, S, Ramia-Angel, J, Malik, H, Stattner, S, Soreide, K, Zmora, O, Meijerink, M, Kartalis, N, Lesurtel, M, Verhoef, C, Balakrishnan, A, Gruenberger, T, Jonas, E, Devar, J, Jamdar, S, Jones, R, Hilal, M, Andersson, B, Boudjema, K, Mullamitha, S, Stassen, L, Dasari, B, Frampton, A, Aldrighetti, L, Pellino, G, Buchwald, P, Gurses, B, Wasserberg, N, Gruenberger, B, Spiers, H, Jarnagin, W, Vauthey, J, Kokudo, N, Tejpar, S, Valdivieso, A, Adam, R, Hauke, L, Smith, M, Deoliveira, M, Adair, A, Gilg, S, Swijnenburg, R, Jaekers, J, Jegatheeswaran, S, Buis, C, Parks, R, Bockhorn, M, Conroy, T, Petras, P, Primavesi, F, Chan, A, Cipriani, F, Rubbia-Brandt, L, Foster, L, Abdelaal, A, Yaqub, S, Rahbari, N, Fondevila, C, Abradelo, M, Kok, N, Tejedor, L, Martinez-Baena, D, Azoulay, D, Maglione, M, Serradilla-Martin, M, Azevedo, J, Romano, F, Line, P, Forcen, T, Panis, Y, Stylianides, N, Bale, R, Quaia, E, Yassin, N, Duque, V, Espin-Basany, E, Mellenhorst, J, Rees, A, Adeyeye, A, Tuynman, J, Simillis, C, Duff, S, Wilson, R, De Nardi, P, Palmer, G, Zakaria, A, Perra, T, Porcu, A, Tamini, N, Kelly, M, Metwally, I, Morarasu, S, Carbone, F, Estaire-Gomez, M, Perez, E, Seligmann, J, Gollins, S, Braun, M, Hessheimer, A, Alonso, V, Radhakrishna, G, Alam, N, Camposorias, C, Barriuoso, J, Ross, P, Ba-Ssalamah, A, Muthu, S, Filobbos, R, Nadarajah, V, Hattab, A, Newton, C, Barker, S, Sibbald, J, Hancock, J, de Liguori Carino, N, Deshpande, R, Lancellotti, F, Paterna, S, Gutierrez-Diez, M, Artigas, C, Siriwardena A. K., Serrablo A., Fretland A. A., Wigmore S. J., Ramia-Angel J. M., Malik H. Z., Stattner S., Soreide K., Zmora O., Meijerink M., Kartalis N., Lesurtel M., Verhoef C., Balakrishnan A., Gruenberger T., Jonas E., Devar J., Jamdar S., Jones R., Hilal M. A., Andersson B., Boudjema K., Mullamitha S., Stassen L., Dasari B. V. M., Frampton A. E., Aldrighetti L., Pellino G., Buchwald P., Gurses B., Wasserberg N., Gruenberger B., Spiers H. V. M., Jarnagin W., Vauthey J. -N., Kokudo N., Tejpar S., Valdivieso A., Adam R., Hauke Lang, Smith M., deOliveira M. L., Adair A., Gilg S., Swijnenburg R. -J., Jaekers J., Jegatheeswaran S., Buis C., Parks R., Bockhorn M., Conroy T., Petras P., Primavesi F., Chan A. K. C., Cipriani F., Rubbia-Brandt L., Foster L., Abdelaal A., Yaqub S., Rahbari N., Fondevila C., Abradelo M., Kok N. F., Tejedor L., Martinez-Baena D., Azoulay D., Maglione M., Serradilla-Martin M., Azevedo J., Romano F., Line P. -D., Forcen T. A., Panis Y., Stylianides N., Bale R., Quaia E., Yassin N., Duque V., Espin-Basany E., Mellenhorst J., Rees A., Adeyeye A., Tuynman J. B., Simillis C., Duff S., Wilson R., De Nardi P., Palmer G. J., Zakaria A. D., Perra T., Porcu A., Tamini N., Kelly M. E., Metwally I., Morarasu S., Carbone F., Estaire-Gomez M., Perez E. M., Seligmann J., Gollins S., Braun M., Hessheimer A., Alonso V., Radhakrishna G., Alam N., Camposorias C., Barriuoso J., Ross P., Ba-Ssalamah A., Muthu S., Filobbos R., Nadarajah V., Hattab A., Newton C., Barker S., Sibbald J., Hancock J., de Liguori Carino N., Deshpande R., Lancellotti F., Paterna S., Gutierrez-Diez M., Artigas C., Siriwardena, A, Serrablo, A, Fretland, A, Wigmore, S, Ramia-Angel, J, Malik, H, Stattner, S, Soreide, K, Zmora, O, Meijerink, M, Kartalis, N, Lesurtel, M, Verhoef, C, Balakrishnan, A, Gruenberger, T, Jonas, E, Devar, J, Jamdar, S, Jones, R, Hilal, M, Andersson, B, Boudjema, K, Mullamitha, S, Stassen, L, Dasari, B, Frampton, A, Aldrighetti, L, Pellino, G, Buchwald, P, Gurses, B, Wasserberg, N, Gruenberger, B, Spiers, H, Jarnagin, W, Vauthey, J, Kokudo, N, Tejpar, S, Valdivieso, A, Adam, R, Hauke, L, Smith, M, Deoliveira, M, Adair, A, Gilg, S, Swijnenburg, R, Jaekers, J, Jegatheeswaran, S, Buis, C, Parks, R, Bockhorn, M, Conroy, T, Petras, P, Primavesi, F, Chan, A, Cipriani, F, Rubbia-Brandt, L, Foster, L, Abdelaal, A, Yaqub, S, Rahbari, N, Fondevila, C, Abradelo, M, Kok, N, Tejedor, L, Martinez-Baena, D, Azoulay, D, Maglione, M, Serradilla-Martin, M, Azevedo, J, Romano, F, Line, P, Forcen, T, Panis, Y, Stylianides, N, Bale, R, Quaia, E, Yassin, N, Duque, V, Espin-Basany, E, Mellenhorst, J, Rees, A, Adeyeye, A, Tuynman, J, Simillis, C, Duff, S, Wilson, R, De Nardi, P, Palmer, G, Zakaria, A, Perra, T, Porcu, A, Tamini, N, Kelly, M, Metwally, I, Morarasu, S, Carbone, F, Estaire-Gomez, M, Perez, E, Seligmann, J, Gollins, S, Braun, M, Hessheimer, A, Alonso, V, Radhakrishna, G, Alam, N, Camposorias, C, Barriuoso, J, Ross, P, Ba-Ssalamah, A, Muthu, S, Filobbos, R, Nadarajah, V, Hattab, A, Newton, C, Barker, S, Sibbald, J, Hancock, J, de Liguori Carino, N, Deshpande, R, Lancellotti, F, Paterna, S, Gutierrez-Diez, M, Artigas, C, Siriwardena A. K., Serrablo A., Fretland A. A., Wigmore S. J., Ramia-Angel J. M., Malik H. Z., Stattner S., Soreide K., Zmora O., Meijerink M., Kartalis N., Lesurtel M., Verhoef C., Balakrishnan A., Gruenberger T., Jonas E., Devar J., Jamdar S., Jones R., Hilal M. A., Andersson B., Boudjema K., Mullamitha S., Stassen L., Dasari B. V. M., Frampton A. E., Aldrighetti L., Pellino G., Buchwald P., Gurses B., Wasserberg N., Gruenberger B., Spiers H. V. M., Jarnagin W., Vauthey J. -N., Kokudo N., Tejpar S., Valdivieso A., Adam R., Hauke Lang, Smith M., deOliveira M. L., Adair A., Gilg S., Swijnenburg R. -J., Jaekers J., Jegatheeswaran S., Buis C., Parks R., Bockhorn M., Conroy T., Petras P., Primavesi F., Chan A. K. C., Cipriani F., Rubbia-Brandt L., Foster L., Abdelaal A., Yaqub S., Rahbari N., Fondevila C., Abradelo M., Kok N. F., Tejedor L., Martinez-Baena D., Azoulay D., Maglione M., Serradilla-Martin M., Azevedo J., Romano F., Line P. -D., Forcen T. A., Panis Y., Stylianides N., Bale R., Quaia E., Yassin N., Duque V., Espin-Basany E., Mellenhorst J., Rees A., Adeyeye A., Tuynman J. B., Simillis C., Duff S., Wilson R., De Nardi P., Palmer G. J., Zakaria A. D., Perra T., Porcu A., Tamini N., Kelly M. E., Metwally I., Morarasu S., Carbone F., Estaire-Gomez M., Perez E. M., Seligmann J., Gollins S., Braun M., Hessheimer A., Alonso V., Radhakrishna G., Alam N., Camposorias C., Barriuoso J., Ross P., Ba-Ssalamah A., Muthu S., Filobbos R., Nadarajah V., Hattab A., Newton C., Barker S., Sibbald J., Hancock J., de Liguori Carino N., Deshpande R., Lancellotti F., Paterna S., Gutierrez-Diez M., and Artigas C.

Abstract

Background: Contemporary management of patients with synchronous colorectal cancer and liver metastases is complex. The aim of this project was to provide a practical framework for care of patients with synchronous colorectal cancer and liver metastases with a focus on terminology, diagnosis and management. Methods: This project was a multi-organisational, multidisciplinary consensus. The consensus group produced statements which focused on terminology, diagnosis and management. Statements were refined during an online Delphi process and those with 70% agreement or above were reviewed at a final meeting. Iterations of the report were shared by electronic mail to arrive at a final agreed document comprising twelve key statements. Results: Synchronous liver metastases are those detected at the time of presentation of the primary tumour. The term “early metachronous metastases” applies to those absent at presentation but detected within 12 months of diagnosis of the primary tumour with “late metachronous metastases” applied to those detected after 12 months. Disappearing metastases applies to lesions which are no longer detectable on MR scan after systemic chemotherapy. Guidance was provided on the recommended composition of tumour boards and clinical assessment in emergency and elective settings. The consensus focused on treatment pathways including systemic chemotherapy, synchronous surgery and the staged approach with either colorectal or liver-directed surgery as first step. Management of pulmonary metastases and the role of minimally invasive surgery was discussed. Conclusions: The recommendations of this contemporary consensus provide information of practical value to clinicians managing patients with synchronous colorectal cancer and liver metastases.

Published
2023

9. Beeldvorming

Author

Vogel, W. V., Hartmann, I. J. C., Lam, M. G. E. H., Meijerink, M. R., van de Velde, C.J.H., editor, van der Graaf, W.T.A., editor, van Krieken, J.H.J.M., editor, and Marijnen, C.A.M., editor

Published
2017
Full Text
View/download PDF

10. Optimizing patient selection for stereotactic ablative radiotherapy in patients with locally advanced pancreatic cancer after initial chemotherapy - a single center prospective cohort

Author

Doppenberg, D., primary, Lagerwaard, F. J., additional, van Dieren, S., additional, Meijerink, M. R., additional, van der Vliet, J. J., additional, Besselink, M. G., additional, van Tienhoven, G., additional, Versteijne, E., additional, Slotman, B. J., additional, Wilmink, J. W., additional, Kazemier, G., additional, and Bruynzeel, A. M. E., additional

Published
2023
Full Text
View/download PDF

17. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy.

Author

UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de chirurgie, UCL - (MGD) Service de radiologie - résonance magnétique, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Claude, Bertrand, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, Jean-François, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, Alexandra, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, van Dam, R M, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de chirurgie, UCL - (MGD) Service de radiologie - résonance magnétique, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Claude, Bertrand, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, Jean-François, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, Alexandra, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, and van Dam, R M

Abstract

The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Not applicable. DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).

Published
2022

18. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR):a nationwide multicenter randomized controlled trial according to a TwiCs design

Author

Doppenberg, D., Besselink, M. G., van Eijck, C. H.J., Intven, M. P.W., Koerkamp, B. Groot, Kazemier, G., van Laarhoven, H. W.M., Meijerink, M., Molenaar, I. Q., Nuyttens, J. J.M.E., van Os, R., van Santvoort, H. C., van Tienhoven, G., Verkooijen, H. M., Versteijne, E., Wilmink, J. W., Lagerwaard, F. J., Bruynzeel, A. M.E., Doppenberg, D., Besselink, M. G., van Eijck, C. H.J., Intven, M. P.W., Koerkamp, B. Groot, Kazemier, G., van Laarhoven, H. W.M., Meijerink, M., Molenaar, I. Q., Nuyttens, J. J.M.E., van Os, R., van Santvoort, H. C., van Tienhoven, G., Verkooijen, H. M., Versteijne, E., Wilmink, J. W., Lagerwaard, F. J., and Bruynzeel, A. M.E.

Abstract

Background: Significant comorbidities, advanced age, and a poor performance status prevent surgery and systemic treatment for many patients with localized (non-metastatic) pancreatic ductal adenocarcinoma (PDAC). These patients are currently treated with ‘best supportive care’. Therefore, it is desirable to find a treatment option which could improve both disease control and quality of life in these patients. A brief course of high-dose high-precision radiotherapy i.e. stereotactic ablative body radiotherapy (SABR) may be feasible. Methods: A nationwide multicenter trial performed within a previously established large prospective cohort (the Dutch Pancreatic cancer project; PACAP) according to the ‘Trial within cohorts’ (TwiCs) design. Patients enrolled in the PACAP cohort routinely provide informed consent to answer quality of life questionnaires and to be randomized according to the TwiCs design when eligible for a study. Patients with localized PDAC who are unfit for chemotherapy and surgery or those who refrain from these treatments are eligible. Patients will be randomized between SABR (5 fractions of 8 Gy) with ‘best supportive care’ and ‘best supportive care’ only. The primary endpoint is overall survival from randomization. Secondary endpoints include preservation of quality of life (EORTC-QLQ-C30 and -PAN26), NRS pain score response and WHO performance scores at baseline, and, 3, 6 and 12 months. Acute and late toxicity will be scored using CTCAE criteria version 5.0: assessed at baseline, day of last fraction, at 3 and 6 weeks, and 3, 6 and 12 months following SABR. Discussion: The PANCOSAR trial studies the added value of SBRT as compared to ‘best supportive care’ in patients with localized PDAC who are medically unfit to receive chemotherapy and surgery, or refrain from these treatments. This study will assess whether SABR, in comparison to best supportive care, can relieve or delay tumor-related symptoms, enhance quality of life, and extend survival

Published
2022

19. Dragon 1 Protocol Manuscript:Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author

Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P.H., Rinkes, I. H.M.Borel, Breitenstein, S., Bruijnen, R. C.G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K.Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K.G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L.J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A.J., Binkert, C. A., Bemelmans, M. H.A., van der Leij, C., Schadde, E., van Dam, R. M., Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P.H., Rinkes, I. H.M.Borel, Breitenstein, S., Bruijnen, R. C.G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K.Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K.G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L.J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A.J., Binkert, C. A., Bemelmans, M. H.A., van der Leij, C., Schadde, E., and van Dam, R. M.

Abstract

Study Purpose: The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods: The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results: Not applicable. Conclusion: DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. Trial Registration: Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).

Published
2022

20. Stereotactic ablative radiotherapy or best supportive care in patients with localized pancreatic cancer not receiving chemotherapy and surgery (PANCOSAR): a nationwide multicenter randomized controlled trial according to a TwiCs design

Author

MS Radiotherapie, Cancer, CTC, MS CGO, MS HOD, Trialbureau Beeld, Arts-assistenten Radiotherapie, Doppenberg, D., Besselink, M. G., van Eijck, C. H.J., Intven, M. P.W., Koerkamp, B. Groot, Kazemier, G., van Laarhoven, H. W.M., Meijerink, M., Molenaar, I. Q., Nuyttens, J. J.M.E., van Os, R., van Santvoort, H. C., van Tienhoven, G., Verkooijen, H. M., Versteijne, E., Wilmink, J. W., Lagerwaard, F. J., Bruynzeel, A. M.E., MS Radiotherapie, Cancer, CTC, MS CGO, MS HOD, Trialbureau Beeld, Arts-assistenten Radiotherapie, Doppenberg, D., Besselink, M. G., van Eijck, C. H.J., Intven, M. P.W., Koerkamp, B. Groot, Kazemier, G., van Laarhoven, H. W.M., Meijerink, M., Molenaar, I. Q., Nuyttens, J. J.M.E., van Os, R., van Santvoort, H. C., van Tienhoven, G., Verkooijen, H. M., Versteijne, E., Wilmink, J. W., Lagerwaard, F. J., and Bruynzeel, A. M.E.

Published
2022

21. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy

Author

Zorgeenheid Orthopaedie Medisch, MS Radiologie, MS CGO, Regenerative Medicine and Stem Cells, Cancer, Other research (not in main researchprogram), Experimentele Afdeling Longziekten, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Bertrand, C L, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, J F, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, A, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, van Dam, R M, Zorgeenheid Orthopaedie Medisch, MS Radiologie, MS CGO, Regenerative Medicine and Stem Cells, Cancer, Other research (not in main researchprogram), Experimentele Afdeling Longziekten, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Bertrand, C L, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, J F, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, A, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, and van Dam, R M

Published
2022

22. Algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection in the Netherlands: an open-label, nationwide, stepped-wedge cluster-randomised trial

Author

Smits, F Jasmijn, primary, Henry, Anne Claire, additional, Besselink, Marc G, additional, Busch, Olivier R, additional, van Eijck, Casper H, additional, Arntz, Mark, additional, Bollen, Thomas L, additional, van Delden, Otto M, additional, van den Heuvel, Daniel, additional, van der Leij, Christiaan, additional, van Lienden, Krijn P, additional, Moelker, Adriaan, additional, Bonsing, Bert A, additional, Borel Rinkes, Inne H, additional, Bosscha, Koop, additional, van Dam, Ronald M, additional, Derksen, Wouter J M, additional, den Dulk, Marcel, additional, Festen, Sebastiaan, additional, Groot Koerkamp, Bas, additional, de Haas, Robbert J, additional, Hagendoorn, Jeroen, additional, van der Harst, Erwin, additional, de Hingh, Ignace H, additional, Kazemier, Geert, additional, van der Kolk, Marion, additional, Liem, Mike, additional, Lips, Daan J, additional, Luyer, Misha D, additional, de Meijer, Vincent E, additional, Mieog, J Sven, additional, Nieuwenhuijs, Vincent B, additional, Patijn, Gijs A, additional, te Riele, Wouter W, additional, Roos, Daphne, additional, Schreinemakers, Jennifer M, additional, Stommel, Martijn W J, additional, Wit, Fennie, additional, Zonderhuis, Babs A, additional, Daamen, Lois A, additional, van Werkhoven, C Henri, additional, Molenaar, I Quintus, additional, van Santvoort, Hjalmar C, additional, Blomjous, JG, additional, de Boer, MT, additional, van den Boezem, P, additional, Bouwense, S, additional, Bruijnen, R, additional, Buis, CI, additional, del Chiaro, M, additional, Coene, PP, additional, Coolsen, M, additional, Daams, F, additional, Dejong, K, additional, Draaisma, W, additional, Eker, HH, additional, Elsen, AH, additional, Gerhards, MF, additional, Hartog, H, additional, Hoogwater, FJ, additional, Imani, F, additional, Jenniskens, S, additional, de Jong, KP, additional, Karsten, TM, additional, Klaase, JM, additional, de Kleine, RHJ, additional, van Laarhoven, CJ, additional, van der Lelij, H, additional, Manusama, ER, additional, Meerdink, M, additional, Meijerink, M, additional, Nederend, J, additional, Nijkamp, MW, additional, Nota, CL, additional, Porte, RJ, additional, Reef, J, additional, de Reuver, P, additional, van Rijswijk, C, additional, Romkens, T, additional, Rupert, C, additional, van der Schelling, GP, additional, Serafino, JP, additional, Vos, LD, additional, Vriens, MR, additional, Beers-Vural, E, additional, Wagtenberg, JM, additional, Wijsman, JH, additional, de Wilde, RF, additional, Wolfgang, CL, additional, and Zeh, HJ, additional

Published
2022
Full Text
View/download PDF

24. Individual-patient meta-analysis of three randomized trials comparing endovascular versus open repair for ruptured abdominal aortic aneurysm

Author

Sweeting, M. J., Balm, R., Desgranges, P., Ulug, P., Powell, J. T., Koelemay, M. J. W., Idu, M. M., Kox, C., Legemate, D. A., Huisman, L. C., Willems, M. C. M., Reekers, J. A., van Delden, O. M., van Lienden, K. P., Hoornweg, L. L., Reimerink, J. J., van Beek, S. C., Vahl, A. C., Leijdekkers, V. J., Bosma, J., Montauban van Swijndregt, A. D., de Vries, C., van der Hulst, V. P. M., Peringa, J., Blomjous, J. G. A. M., Visser, M. J. T., van der Heijden, F. H. W. M., Wisselink, W., Hoksbergen, A. W. J., Blankensteijn, J. D., Visser, M. T. J., Coveliers, H. M. E., Nederhoed, J. H., van den Berg, F. G., van der Meijs, B. B., van den Oever, M. L. P., Lely, R. J., Meijerink, M. R., Voorwinde, A., Ultee, J. M., van Nieuwenhuizen, R. C., Dwars, B. J., Nagy, T. O. M., Tolenaar, P., Wiersema, A. M., Lawson, J. A., van Aken, P. J., Stigter, A. A., van den Broek, T. A. A., Vos, G. A., Mulder, W., Strating, R. P., Nio, D., Akkersdijk, G. J. M., van der Elst, A., van Exter, P., Becquemin, J.-P., Allaire, E., Cochennec, F., Marzelle, J., Louis, N., Schneider, J., Majewski, M., Castier, Y., Leseche, G., Francis, F., Steinmetz, E., Berne, J.-P., Favier, C., Haulon, S., Koussa, M., Azzaoui, R., Piervito, D., Alimi, Y., Boufi, M., Hartung, O., Cerquetta, P., Amabile, P., Piquet, P., Penard, J., Demasi, M., Alric, P., Canaud, L., Berthet, J.-P., Julia, P., Fabiani, J.-N., Alsac, J. M., Gouny, P., Badra, A., Braesco, J., Favre, J.-P., Albertini, J.-N., Martinez, R., Hassen-Khodja, R., Batt, M., Jean, E., Sosa, M., Declemy, S., Destrieux-Garnier, L., Lermusiaux, P., Feugier, P., Ashleigh, R., Gomes, M., Greenhalgh, R. M., Grieve, R., Hinchliffe, R., Sweeting, M., Thompson, M. M., Thompson, S. G., Cheshire, N. J., Boyle, J. R., Serracino-Inglott, F., Smyth, J. V., Hinchliffe, R. J., Bell, R., Wilson, N., Bown, M., Dennis, M., Davis, M., Howell, S., Wyatt, M. G., Valenti, D., Bachoo, P., Walker, P., MacSweeney, S., Davies, J. N., Rittoo, D., Parvin, S. D., Yusuf, W., Nice, C., Chetter, I., Howard, A., Chong, P., Bhat, R., McLain, D., Gordon, A., Lane, I., Hobbs, S., Pillay, W., Rowlands, T., El-Tahir, A., Asquith, J., Cavanagh, S., Dubois, L., and Forbes, T. L.

Published
2015
Full Text
View/download PDF

26. (11)C-Sorafenib and (15)O-H(2)O PET for Early Evaluation of Sorafenib Therapy

Author

Mammatas, L.H., Yaqub, M., Hendrikse, N.H., Hoekstra, O.S., Honeywell, R.J., Schuit, R.C., Meijerink, M., Schwarte, L.A., Peters, G.J., Verheul, H.M.W., Lammertsma, A.A., Menke-van der Houven van Oordt, C.W., Mammatas, L.H., Yaqub, M., Hendrikse, N.H., Hoekstra, O.S., Honeywell, R.J., Schuit, R.C., Meijerink, M., Schwarte, L.A., Peters, G.J., Verheul, H.M.W., Lammertsma, A.A., and Menke-van der Houven van Oordt, C.W.

Abstract

Contains fulltext : 238182.pdf (Publisher’s version ) (Closed access), Sorafenib leads to clinical benefit in a subgroup of patients, whereas all are exposed to potential toxicity. Currently, no predictive biomarkers are available. The purpose of this study was to evaluate whether (11)C-sorafenib and (15)O-H(2)O PET have potential to predict treatment efficacy. Methods: In this prospective exploratory study, 8 patients with advanced solid malignancies and an indication for sorafenib treatment were included. Microdose (11)C-sorafenib and perfusion (15)O-H(2)O dynamic PET scans were performed before and after 2 wk of sorafenib therapy. The main objective was to assess whether tumor (11)C-sorafenib uptake predicts sorafenib concentrations during therapy in corresponding tumor biopsy samples measured with liquid chromatography tandem mass spectrometry. Secondary objectives included determining the association of (11)C-sorafenib PET findings, perfusion (15)O-H(2)O PET findings, and sorafenib concentrations after therapeutic dosing with response. Results: (11)C-sorafenib PET findings did not predict sorafenib concentrations in tumor biopsy samples during therapy. In addition, sorafenib plasma and tumor concentrations were not associated with clinical outcome in this exploratory study. Higher (11)C-sorafenib accumulation in tumors at baseline and day 14 of treatment showed an association with poorer prognosis and correlated with tumor perfusion (Spearman correlation coefficient = 0.671, P = 0.020). Interestingly, a decrease in tumor perfusion measured with (15)O-H(2)O PET after only 14 d of therapy showed an association with response, with a decrease in tumor perfusion of 56% ± 23% (mean ± SD) versus 18% ± 32% in patients with stable and progressive disease, respectively. Conclusion: Microdose (11)C-sorafenib PET did not predict intratumoral sorafenib concentrations after therapeutic dosing, but the association between a decrease in tumor perfusion and clinical benefit warrants further investigation.

Published
2021

31. GGD-richtlijn medische milieukunde : Veehouderij en gezondheid

Author

Nijdam, R, Dusseldorp, A, Elders-Meijerink, M, Jacobs, P, Maassen, CBM, van der Lelie, S, Pasnagel, M, van Strien, R, van de Waal, N, van de Weerdt, R, and Zock, JP

Subjects
RIVM rapport 2020-0092
Abstract

De aanwezigheid van intensieve veehouderij kan invloed hebben op de gezondheid van omwonenden. De GGD'en hebben de richtlijn 'Veehouderij en gezondheid' ontwikkeld zodat ze op dezelfde manier hierover kunnen adviseren. De coördinatie van de richtlijn ligt bij het RIVM. De richtlijn beschrijft de huidige kennis over veehouderij en gezondheid. Ook geeft de richtlijn input voor gezondheidskundige adviezen voor omwonenden in verschillende situaties. Denk aan de uitbreiding of vestiging van veehouderijbedrijven, of de gebiedsinrichting van het platteland. Er is veel gezondheidswinst te behalen wanneer goed wordt nagedacht over de ruimtelijke inrichting, dus bij het opstellen van omgevingsvisies en plannen. Daarom is de GGD bij voorkeur vroeg in dit proces betrokken. De GGD heeft twee uitgangspunten bij zijn adviezen. De eerste is voorzorg: wees terughoudend met het plaatsen van gevoelige bestemmingen en veehouderijen binnen 250 meter van elkaar (bij geitenhouderijen binnen 2 kilometer). Gevoelige bestemmingen zijn bijvoorbeeld woningen, scholen, en ziekenhuizen. Het tweede uitgangspunt is het streven om de uitstoot van geur, stof, endotoxinen (kleine stukjes bacteriën) en ammoniak van veehouderijen te verminderen.

Published
2020

32. Preoperative imaging for colorectal liver metastases:a nationwide population-based study

Author

Elfrink, A K E, Pool, M, van der Werf, L R, Marra, E, Burgmans, M C, Meijerink, M R, den Dulk, M, van den Boezem, P B, Te Riele, W W, Patijn, G A, Wouters, M W J M, Leclercq, W K G, Liem, M S L, Gobardhan, P D, Buis, C I, Kuhlmann, K F D, Verhoef, C, Besselink, M G, Grünhagen, D J, Klaase, J M, Kok, N F M, Elfrink, A K E, Pool, M, van der Werf, L R, Marra, E, Burgmans, M C, Meijerink, M R, den Dulk, M, van den Boezem, P B, Te Riele, W W, Patijn, G A, Wouters, M W J M, Leclercq, W K G, Liem, M S L, Gobardhan, P D, Buis, C I, Kuhlmann, K F D, Verhoef, C, Besselink, M G, Grünhagen, D J, Klaase, J M, and Kok, N F M

Abstract

BACKGROUND: In patients with colorectal liver metastases (CRLM) preoperative imaging may include contrast-enhanced (ce) MRI and [18 F]fluorodeoxyglucose (18 F-FDG) PET-CT. This study assessed trends and variation between hospitals and oncological networks in the use of preoperative imaging in the Netherlands.METHODS: Data for all patients who underwent liver resection for CRLM in the Netherlands between 2014 and 2018 were retrieved from a nationwide auditing database. Multivariable logistic regression analysis was used to assess use of ceMRI, 18 F-FDG PET-CT and combined ceMRI and 18 F-FDG PET-CT, and trends in preoperative imaging and hospital and oncological network variation.RESULTS: A total of 4510 patients were included, of whom 1562 had ceMRI, 872 had 18 F-FDG PET-CT, and 1293 had combined ceMRI and 18 F-FDG PET-CT. Use of ceMRI increased over time (from 9·6 to 26·2 per cent; P < 0·001), use of 18 F-FDG PET-CT decreased (from 28·6 to 6·0 per cent; P < 0·001), and use of both ceMRI and 18 F-FDG PET-CT 16·9 per cent) remained stable. Unadjusted variation in the use of ceMRI, 18 F-FDG PET-CT, and combined ceMRI and 18 F-FDG PET-CT ranged from 5·6 to 100 per cent between hospitals. After case-mix correction, hospital and oncological network variation was found for all imaging modalities.DISCUSSION: Significant variation exists concerning the use of preoperative imaging for CRLM between hospitals and oncological networks in the Netherlands. The use of MRI is increasing, whereas that of 18 F-FDG PET-CT is decreasing.

Published
2020

36. The treatment of older patients with locally advanced pancreatic cancer. A prospective cohort study.

Author

Brada, L., primary, Walma, M., additional, Van Dam, R., additional, De Vos-Geelen, J., additional, De Hingh, I., additional, Creemers, G., additional, Liem, M., additional, Mekenkamp, L., additional, De Meijer, V., additional, De Groot, D., additional, Patijn, G., additional, De Groot, W., additional, Festen, S., additional, Kerver, E., additional, Stommel, M., additional, Meijerink, M., additional, Bosscha, K., additional, Pruijt, H., additional, Polée, M., additional, Ropela, A., additional, Cirkel, G., additional, Los, M., additional, Wilmink, H., additional, Haj Mohammad, N., additional, Van Santvoort, H., additional, Besselink, M., additional, and Molenaar, Q., additional

Published
2020
Full Text
View/download PDF

37. Development and internal validation of two nomograms predicting outcomes in patients with locally advanced pancreatic cancer starting treatment with FOLFIRINOX

Author

Brada, L., primary, Walma, M., additional, Daamen, L., additional, Van Roessel, S., additional, Van Dam, R., additional, De Hingh, I., additional, Liem, M., additional, De Meijer, V., additional, Patijn, G., additional, Festen, S., additional, Stommel, M., additional, Meijerink, M., additional, Bosscha, K., additional, Polée, M., additional, Ropela, A., additional, Nio, Y., additional, Wessels, F., additional, Van Leeuwen, M., additional, De Vries, J., additional, Van Lienden, K., additional, Bruijnen, R., additional, Busch, O., additional, Besselink, M., additional, Molenaar, Q., additional, and Van Santvoort, H., additional

Published
2020
Full Text
View/download PDF

38. Preoperative imaging for colorectal liver metastases: a nationwide population-based study

Author

Elfrink, A K E, primary, Pool, M, additional, Werf, L R, additional, Marra, E, additional, Burgmans, M C, additional, Meijerink, M R, additional, Dulk, M, additional, Boezem, P B, additional, Riele, W W, additional, Patijn, G A, additional, Wouters, M W J M, additional, Leclercq, W K G, additional, Liem, M S L, additional, Gobardhan, P D, additional, Buis, C I, additional, Kuhlmann, K F D, additional, Verhoef, C, additional, Besselink, M G, additional, Grünhagen, D J, additional, Klaase, J M, additional, and Kok, N F M, additional

Published
2020
Full Text
View/download PDF

40. 4:12 PM Abstract No. 40 Transcatheter computed tomography hepatic arteriography compared to conventional computed tomography fluoroscopy guidance in percutaneous thermal ablation to treat colorectal liver metastases: a single-center comparative analysis of two historical cohorts

Author

Puijk, R., primary, Bemd, B., additional, Nieuwenhuizen, S., additional, Ruarus, A., additional, Vroomen, L., additional, Jong, M., additional, Geboers, B., additional, Vries, J., additional, Tol, P., additional, Scheffer, H., additional, and Meijerink, M., additional

Published
2020
Full Text
View/download PDF

42. The ORCHESTRA trial; A phase III trial of adding tumour debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC)

Author

Bakkerus, L., Gootjes, E. C., van der Stok, E. P., Buffart, T. E., Zonderhuis, B. M., Tuynman, J. B., Meijerink, M. P., van de Ven, P. M., Haasbeek, C. J., Ten Tije, A. J., de Groot, J. W., Radema, S. A., Hendriks, M. P., Helgason, H. H., van Meerten, E., Nuyttens, J. J., Grunhagen, D. J., Verhoef, C., Verheul, H. M. W., Medical oncology, Internal medicine, Surgery, AGEM - Re-generation and cancer of the digestive system, CCA - Cancer Treatment and quality of life, Radiology and nuclear medicine, APH - Methodology, Epidemiology and Data Science, Radiation Oncology, Cardiology, and ACS - Heart failure & arrhythmias

Published
2019

43. GGD-richtlijn medische milieukunde : Luchtkwaliteit en gezondheid

Author

Dam-Deisz WDC, Broek I van den, Odink J, Zee S van der, Zuurbier M, Aarts F, Buggenum S van, Elders-Meijerink M, Fischer P, Hout K van den, Jansen H, Keuken R, Leeuwen A van, Ovaa W, MNS, and VLH

Subjects
RIVM rapport 2018-0016, luchtkwaliteit, milieubeleid, environmental policy, health risks, fijn stof, air quality, Gezondheidsrisico's, partculate matter
Abstract

Het RIVM en de GGD'en hebben de GGD-richtlijn 'Luchtkwaliteit en Gezondheid' uit 2008 geactualiseerd. De vernieuwde richtlijn biedt onder meer een actueel overzicht van wetenschappelijke studies naar gezondheid en luchtkwaliteit en de betekenis van nieuwe (Europese) beleidsontwikkelingen. Ook wordt uitgelegd hoe luchtkwaliteit wordt gemeten en berekend. De nadruk ligt op wegverkeer-gerelateerde luchtverontreiniging, maar ook de invloed van bijvoorbeeld andere verkeersbronnen (zoals scheepvaart en brommers), industrie, landbouw en houtrook op de luchtkwaliteit komt aan bod. De richtlijn is geactualiseerd, omdat de kennis over luchtverontreiniging en de effecten op de gezondheid de afgelopen jaren zijn toegenomen. Een betere luchtkwaliteit levert gezondheidswinst op, ook als de concentraties luchtvervuilende stoffen onder de gestelde normen liggen. Hoewel de luchtkwaliteit de laatste decennia is verbeterd, worden op een aantal locaties in Nederland de Europese grenswaarden overschreden. Verbetering is noodzakelijk om deze situaties positief te beïnvloeden en toekomstige hoge blootstellingen aan vervuilende stoffen te voorkomen. De richtlijn is een hulpmiddel voor de GGD'en om gemeenten en provincies te adviseren en burgers te informeren over de lokale luchtkwaliteit. GGD'en kunnen voorstellen doen om de luchtkwaliteit te verbeteren en advies geven over de ruimtelijke inrichting nabij drukke verkeerswegen. Op basis van advies van de GGD kunnen gemeenten aanvullend lokaal beleid formuleren om de bevolking, en hooggevoelige groepen in het bijzonder, te beschermen. Daarnaast kan de GGD erop wijzen dat goede communicatie tussen gemeenten en de bevolking over dit onderwerp belangrijk is en hiervoor praktische adviezen geven. De GGD-richtlijnen medische milieukunde (MMK) zijn bedoeld om het handelen van GGD'en te harmoniseren en te optimaliseren.

Published
2018

44. Thermal Effects of Irreversible Electroporation

Author

van Veldhuisen, Eran, Klaessens, J. H., Verdaasdonk, Rudolf M., Meijerink, M., Scheffer, H., Narayanan, G., CCA - Cancer Treatment and Quality of Life, AGEM - Re-generation and cancer of the digestive system, AGEM - Digestive immunity, Graduate School, and Surgery

Subjects
Cell membrane, Thermal techniques, Programmed cell death, medicine.anatomical_structure, Chemistry, fungi, Cell, medicine, Biophysics, Severe morbidity, Thermal damage, Irreversible electroporation, Bile leakage
Abstract

Although irreversible electroporation (IRE) is thought to be a nonthermal technique for the ablation of soft tissue, objective temperature measurements and mathematical models have shown that temperature increase during treatment can be significant. The nonthermal mechanism is thought to be caused by a disturbance in the cell’s homeostasis through the formation of nanopores in the cell membrane, making it permeable for its contents. However, histologically, thermal damage is also observed. Therefore the mechanism of irreversible electroporation is presumed to be a combination of these effects. Thermal energy produced during treatment with IRE can both be a contributory factor to cell death and can potentially also be harmful in the presence of thermally vulnerable structures. Previous studies with purely thermal techniques in the pancreas and liver have shown potential severe morbidity such as bleedings and bile leakage.

Published
2018

47. GGD-richtlijn medische milieukunde : Luchtkwaliteit en gezondheid

Author

MNS, VLH, Dam-Deisz WDC, Broek I van den, Odink J, Zee S van der, Zuurbier M, Aarts F, Buggenum S van, Elders-Meijerink M, Fischer P, Hout K van den, Jansen H, Keuken R, Leeuwen A van, Ovaa W, MNS, VLH, Dam-Deisz WDC, Broek I van den, Odink J, Zee S van der, Zuurbier M, Aarts F, Buggenum S van, Elders-Meijerink M, Fischer P, Hout K van den, Jansen H, Keuken R, Leeuwen A van, and Ovaa W

Abstract

RIVM rapport:Het RIVM en de GGD'en hebben de GGD-richtlijn 'Luchtkwaliteit en Gezondheid' uit 2008 geactualiseerd. De vernieuwde richtlijn biedt onder meer een actueel overzicht van wetenschappelijke studies naar gezondheid en luchtkwaliteit en de betekenis van nieuwe (Europese) beleidsontwikkelingen. Ook wordt uitgelegd hoe luchtkwaliteit wordt gemeten en berekend. De nadruk ligt op wegverkeer-gerelateerde luchtverontreiniging, maar ook de invloed van bijvoorbeeld andere verkeersbronnen (zoals scheepvaart en brommers), industrie, landbouw en houtrook op de luchtkwaliteit komt aan bod. De richtlijn is geactualiseerd, omdat de kennis over luchtverontreiniging en de effecten op de gezondheid de afgelopen jaren zijn toegenomen. Een betere luchtkwaliteit levert gezondheidswinst op, ook als de concentraties luchtvervuilende stoffen onder de gestelde normen liggen. Hoewel de luchtkwaliteit de laatste decennia is verbeterd, worden op een aantal locaties in Nederland de Europese grenswaarden overschreden. Verbetering is noodzakelijk om deze situaties positief te beïnvloeden en toekomstige hoge blootstellingen aan vervuilende stoffen te voorkomen. De richtlijn is een hulpmiddel voor de GGD'en om gemeenten en provincies te adviseren en burgers te informeren over de lokale luchtkwaliteit. GGD'en kunnen voorstellen doen om de luchtkwaliteit te verbeteren en advies geven over de ruimtelijke inrichting nabij drukke verkeerswegen. Op basis van advies van de GGD kunnen gemeenten aanvullend lokaal beleid formuleren om de bevolking, en hooggevoelige groepen in het bijzonder, te beschermen. Daarnaast kan de GGD erop wijzen dat goede communicatie tussen gemeenten en de bevolking over dit onderwerp belangrijk is en hiervoor praktische adviezen geven. De GGD-richtlijnen medische milieukunde (MMK) zijn bedoeld om het handelen van GGD'en te harmoniseren en te optimaliseren., Since the knowledge about air pollution and its effects on health has increased in recent years, the National Institute for Public Health and the Environment (RIVM) and Municipal Public Health Services (GGDs) in the Netherlands have updated the GGD guideline 'Air quality and health', published in 2008. The revised guideline provides an up-to-date overview of scientific studies on health and air quality and discusses the implications of recent developments in (European) policies. In addition, the guideline explains how air quality can be measured and calculated. The emphasis is on road traffic-related air pollution. However, the influence on air quality of other traffic-related sources (such as shipping and mopeds), industry, agriculture and wood smoke is also taken into account. Improved air quality results in health gains, even if the concentrations of air pollutants are below the set standards. Although air quality has improved in recent decades, the standards are exceeded at a number of locations in the Netherlands. Improvement of air quality is necessary to positively influence these situations and to prevent future high exposures to pollutants. The guideline is a tool to be used by GGDs when advising local authorities and informing the public about local air quality. The GGD can propose measures to improve air quality and can advise on spatial planning near busy roads. Local authorities can use the GGD advice as a basis for additional local policies in order to protect the population and, in particular, vulnerable groups. In addition, the GGD can emphasize the importance of a dialogue on this subject between local authorities and the public, and can provide practical advice to support this process. The GGD guidelines for environmental health (MMK) are intended to harmonise and optimise the work of GGDs. This guideline may be deviated from in accordance with the local situation.

Published
2018

48. Time-Dependent Impact of Irreversible Electroporation on Pancreas, Liver, Blood Vessels and Nerves: A Systematic Review of Experimental Studies (vol 11, e0166987, 2016)

Author

Vogel, J. A., van Veldhuisen, E., Agnass, P., Crezee, J., Dijk, F., Verheij, J., van Gulik, T. M., Meijerink, M. R., Vroomen, L. G., van Lienden, K. P., Besselink, M. G., CCA - Cancer Treatment and Quality of Life, Graduate School, Cancer Center Amsterdam, Radiotherapy, Pathology, Amsterdam Gastroenterology Endocrinology Metabolism, Surgery, Radiology and Nuclear Medicine, and APH - Methodology

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0166987.]

Published
2017

50. Lactobacillus plantarum Strains Can Enhance Human Mucosal and Systemic Immunity and Prevent Non-steroidal Anti-inflammatory Drug Induced Reduction in T Regulatory Cells

Author

Vos, Paul de, Mujagic, Z., Haan, B.J. de, Siezen, R.J., Bron, P.A., Meijerink, M., Wells, J.M., Masclee, A.A.M., Boekschoten, M.V., Faas, M.M., Troost, F.J., Vos, Paul de, Mujagic, Z., Haan, B.J. de, Siezen, R.J., Bron, P.A., Meijerink, M., Wells, J.M., Masclee, A.A.M., Boekschoten, M.V., Faas, M.M., and Troost, F.J.

Abstract

Contains fulltext : 176878.pdf (publisher's version ) (Open Access), Orally ingested bacteria interact with intestinal mucosa and may impact immunity. However, insights in mechanisms involved are limited. In this randomized placebo-controlled cross-over trial, healthy human subjects were given Lactobacillus plantarum supplementation (strain TIFN101, CIP104448, or WCFS1) or placebo for 7 days. To determine whether L. plantarum can enhance immune response, we compared the effects of three stains on systemic and gut mucosal immunity, by among others assessing memory responses against tetanus toxoid (TT)-antigen, and mucosal gene transcription, in human volunteers during induction of mild immune stressor in the intestine, by giving a commonly used enteropathic drug, indomethacin [non-steroidal anti-inflammatory drug (NSAID)]. Systemic effects of the interventions were studies in peripheral blood samples. NSAID was found to induce a reduction in serum CD4+/Foxp3 regulatory cells, which was prevented by L. plantarum TIFN101. T-cell polarization experiments showed L. plantarum TIFN101 to enhance responses against TT-antigen, which indicates stimulation of memory responses by this strain. Cell extracts of the specific L. plantarum strains provoked responses after WCFS1 and TIFN101 consumption, indicating stimulation of immune responses against the specific bacteria. Mucosal immunomodulatory effects were studied in duodenal biopsies. In small intestinal mucosa, TIFN101 upregulated genes associated with maintenance of T- and B-cell function and antigen presentation. Furthermore, L. plantarum TIFN101 and WCFS1 downregulated immunological pathways involved in antigen presentation and shared downregulation of snoRNAs, which may suggest cellular destabilization, but may also be an indicator of tissue repair. Full sequencing of the L. plantarum strains revealed possible gene clusters that might be responsible for the differential biological effects of the bacteria on host immunity. In conclusion, the impact of oral consumption L. plantarum on host

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results